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Abstract
Background: Depression is among the major contributors to worldwide disease burden and
adequate modelling requires a framework designed to depict real world disease progression as well
as its economic implications as closely as possible.
Objectives: In light of the specific characteristics associated with depression (multiple episodes at
varying intervals, impact of disease history on course of illness, sociodemographic factors), our aim
was to clarify to what extent "Discrete Event Simulation" (DES) models provide methodological
benefits in depicting disease evolution.
Methods: We conducted a comprehensive review of published Markov models in depression and
identified potential limits to their methodology. A model based on DES principles was developed
to investigate the benefits and drawbacks of this simulation method compared with Markov
modelling techniques.
Results: The major drawback to Markov models is that they may not be suitable to tracking
patients' disease history properly, unless the analyst defines multiple health states, which may lead
to intractable situations. They are also too rigid to take into consideration multiple patient-specific
sociodemographic characteristics in a single model. To do so would also require defining multiple
health states which would render the analysis entirely too complex. We show that DES resolve
these weaknesses and that its flexibility allow patients with differing attributes to move from one
event to another in sequential order while simultaneously taking into account important risk
factors such as age, gender, disease history and patients attitude towards treatment, together with
any disease-related events (adverse events, suicide attempt etc.).
Conclusion: DES modelling appears to be an accurate, flexible and comprehensive means of
depicting disease progression compared with conventional simulation methodologies. Its use in
analysing recurrent and chronic diseases appears particularly useful compared with Markov
processes.
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I. Background
Depression is a widespread condition associated with sig-
nificant functional and social deterioration as well as
extensive direct and indirect health care costs. A recent
review of epidemiological studies estimates the annual
prevalence rate of major depression at approximately 5%
in Europe [1]. Within the next 20 years, depression is pre-
dicted to become one of the leading causes of disability
worldwide [2].
In 2001, the National Institute of Mental Health author-
ized additional research on preventing relapse in major
depression as a part of a larger effort to find effective treat-
ments capable of producing long-term durable recovery
[3]. Depression is a recurrent, potentially chronic and dis-
abling condition. Acute treatments for depression,
although effective, are often not sufficient enough for a
large percentage of patients in preventing either subse-
quent functional impairment due to residual symptoms,
or recurrent episodes. The primary objective of an inter-
vention to prevent relapse is sustained remission of
depressive symptoms. However, it is increasingly accepted
that economic considerations need to be taken into
account. Rising costs of interventions along with newer
and more expensive antidepressant treatments bring up to
questions about the cost-effectiveness of therapeutic inter-
ventions. Economic evaluation can assist decision-makers
by providing additional support in making informed
judgments concerning the allocation of increasingly
scarce healthcare resources [4].
Quantifying the economic implications of a healthcare
intervention requires precisely defining the target popula-
tion, the characteristics of the disease and the therapeutic
intervention. It also requires structuring the possible tra-
jectory of patients in a logical, realistic order over time by
considering the events that may occur, together with their
health and economic implications. Providing a computa-
tional framework to illustrate disease progression over
time as accurately as possible is necessary. Decision trees
have been used successfully despite general recognition
that they have severe limitations when applied to medical
conditions [5]. Markov models provided an alternative
that allowed analysts to picture the course of a disease in
terms of mutually exclusive health states and the transi-
tions among them. While this technique considers time
more explicitly and can be analyzed very efficiently,
Markov models are considered highly rigid, mainly
because of the lack of 'memory' imposed by the stochastic
process.
Discrete Event Simulation (DES) models might offer a
natural way of adequately depicting patient disease course
throughout the health system [6] by making it possible to
take into account important (baseline) prognostic factors
together with life events interactions.
In this case study, our intention was to identify and com-
pare the strengths and limits of discrete event simulation
models with those of Markov models in portraying
depression dynamics. To achieve this goal we employed a
three-step process:
1. We described the clinical features specific to unipolar
major depression.
2. We conducted a conceptual implementation of a
Markov model and a DES model to detect possible abili-
ties to address disease-specific issues relevant to major
depression.
3. We discussed and compared the ability of each type of
model to adequately reflect disease progression over time.
II. Key clinical features of unipolar depression
MB. Keller and colleagues reviewed important factors pre-
disposing patients to recurrence of depressive symptoms
and highlighted several risk factors that should be consid-
ered when modelling disease evolution [7].
II.1 Definitions
Concentrating on prophylactic strategies requires consen-
sus of definitions for specific concepts such as relapse and
recurrences  of depressive symptoms. In 1988, the
MacArthur Foundation Research Network on the Psycho-
biology of Depression consensus group agreed on the def-
inition of terms required to designate the relevant change
points over the course of illness. These definitions have
provided a framework for deciding what constitutes "an
episode" and have further clarified the concepts of severity
and duration.
￿ Remission is defined as "a relatively brief period during
which an improvement of sufficient magnitude is
observed so that the individual is asymptomatic, i.e. the
patient no longer meets syndromal criteria for the disor-
der and has no more than minimal symptoms".
￿ Recovery is defined as "an asymptomatic period that
lasts longer than the remission period". This definition is
used to designate recovery from the episode, not from the
depressive symptoms per se, and implies a sustained
remission of symptoms.
￿ Relapse is defined as "the early return of depressive
symptoms following an apparent remission".Cost Effectiveness and Resource Allocation 2006, 4:19 http://www.resource-allocation.com/content/4/1/19
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￿ Recurrence is defined as "the appearance of a new epi-
sode of major depressive disorder and thus can only occur
during a period of recovery".
Figure 1 provides a visual understanding of how distinct
phases of depression differentiate relapses from recur-
rences, and remission from full recovery.
In this paper, a "depressive event" is defined as the occur-
rence of depressive symptoms. A depressive episode may
include several depressive events.
II.2 Important risk factors
The following section highlights key features in terms of
risk factors for unipolar major depression. The illustrative
data presented hereafter were extracted from published lit-
erature [7-10]. Long-term prospective studies of patients
with depression are somewhat scarce, therefore this work
was mainly based on the National Institute of Mental
Health (NIMH) Collaborative Program on the Psychobi-
ology of Depression study [7,9,10]. This study was a pro-
spective, naturalistic long-term follow-up that aimed to
describe the episodic course of illness in major depressive
disorder. Recruited individuals received either outpatient
or inpatient care (outpatients represented 25% of the total
sample).
One of the major findings from this long-term follow-up
study suggested that the number of previous depressive
events a patient experienced significantly influenced their
probability of relapse (Figure 3).
In approximately 20% of cases, as duration of depressive
symptoms increased, the chances of remission decreased
(Figure 4). These findings reinforce the chronic nature of
the illness for a substantial number of patients [11].
The presence of residual depressive symptoms has also
been proven to be associated with an increased risk of
short-term relapse as well as with a long-term chronic
course. Patients' attitude towards treatment has also been
widely discussed as a key predictive factor of the long-term
course of the disease. Olfson and colleagues [12] recently
showed that approximately 4 out of 10 patients (42.4%)
who initiated antidepressant treatment for depression dis-
continued the antidepressant medication during the first
30 days of treatment, and among those who continued
antidepressant therapy for more than 30 days, one-half
(52.1%) discontinued the medication during the subse-
quent 60-day period. Moreover, a 2-year naturalistic study
showed superior long-term recovery in patients who were
adherent to antidepressant medication compared with
non-adherent patients [8,13].
Diagram of the five possible outcomes across the three phases of treatment of depression (Source: Thase M.E., 2000) Figure 1
Diagram of the five possible outcomes across the three phases of treatment of depression (Source: Thase M.E., 2000). Acute 
phase: usually 2 to 3 months; Continuation phase: usually 4 to 6 months; Maintenance phase: can last up to 5 years (Definitions 
from Kupfer et al. study, 1992)Cost Effectiveness and Resource Allocation 2006, 4:19 http://www.resource-allocation.com/content/4/1/19
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Lastly, sociodemographic characteristics such as age and
gender have also been proven to be significant factors to
be taken into consideration [14].
Figure 2 summarizes the key factors for recurrent depres-
sion.
Management of patients therefore requires differentiating
between their sociodemographic characteristics, disease
history, number of prior episodes and compliance to
treatment over time.
III. Application
Acceptance of the definitions proposed brings us to the
comparison of two computational frameworks for model-
ling real-life disease evolution for in- and outpatients with
major unipolar depression over a period of 10 years.
The final health outcomes of interest were time spent
without depressive symptoms (i.e. time in remission and
full recovery) and the number of relapses and recurrences
occurring over the study period. The simulation models
described hereafter illustrate disease progression over
time regardless of therapeutic strategy and take into con-
sideration realistic patient behaviour patterns as well as
important prognostic factors. We provide additional tech-
nical details on both Markov and Discrete Event Simula-
tion models, together with a practical example of both
modelling methods. The software used to implement the
simulation models was TreeAge Pro 2006 Healthcare Soft-
ware, release 0.1 by TreeAge Software Inc., Williamstown,
MA 01267 USA.
III.1 Markov models
Markov modelling is a decision-analytic technique that
characterizes the prognosis of a cohort of patients by
assigning them to a fixed number of health states and then
models transitions among health states [15]. Markov
models (typically Markov chains) assume transition prob-
abilities to be constant over time. However, it's possible to
bypass this strict assumption by modelling non-homoge-
neous (i.e. time-dependent) Markovian stochastic proc-
esses. Markov models are particularly suited to modelling
events of interest that occur repeatedly over a long period
of time [5,15]. However, an important limitation of
Markov models is that they lack "memory". This means
that the probability of moving from one state to another
does not take into account the history of the patient
before he or she arrived in that state. This is also referred
to as the Markovian assumption.
In our illustrative case (picture in Figure 5), health states
were divided into three levels of risk -low, moderate, high
(reflecting patient's number of previous episodes), each
being divided into multiple temporary states associated
with varying probabilities of remission according to the
time elapsed in the disease state (in order to handle illness
persistence issues). Therefore, for each level of risk, on the
basis of a 1-week cycle (the accepted time span in MDD
before observing any potential health transitions), we
defined 24 temporary depressed states, i.e. 24 weekly
remission probabilities adjusted for the duration of the
disease. If the patient was still depressed at week 24, a con-
stant probability of remission was applied. The number of
temporary states was chosen according to the accepted
management of an episode (i.e. a continuation period of
6 months) [16,17].
This resulted in 24*3 = 72 (temporary) health states
accounting for risk levels and duration of the illness.
To differentiate remission periods from recovery periods
(for increased precision when assessing the ability of a
given strategy to further delay development of depressive
symptoms), it was necessary to divide the "well" state into
two separate temporary states. The first state was remis-
sion, i.e. the first 24 weeks following the disappearance of
symptoms (in accordance with clinical guidelines which
define a minimum of 24 symptom-free weeks before con-
cluding that the patient has achieved full recovery). The
second state was the full recovery period (i.e. a period of
remission longer than 24 weeks).
The data required to specify this simulation model (in
terms of clinical data exclusively) are survival distribu-
tions of remission and relapse at each cycle (i.e. one-week
transition probabilities), conditional on the number of
previous depression events. The time spent in the any
health state may be summed over the period (i.e. 10 years
= 520 cycles) and eventually discounted according to
applicable rates.
This somewhat "simple" model (i.e. in terms of the
number of risk factors taken into account) demonstrates
the suitability of Markov models in addressing the key fea-
tures of importance when modelling depression evolu-
Key risk factors for recurrent depression Figure 2
Key risk factors for recurrent depressionCost Effectiveness and Resource Allocation 2006, 4:19 http://www.resource-allocation.com/content/4/1/19
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tion over time. First, they handle the problem of patients'
history of the disease by splitting health states according
to different risk levels (low, moderate, high). This is com-
putationally acceptable. Second, the chronic nature of the
disease (for approximately 20% of patients, as mentioned
previously) was managed at the expense of defining mul-
tiple health states (i.e. 72 states encoded as "tunnel" vari-
ables), making it possible to assign varying transition
probabilities according to the time spent in the
"depressed" state. Lastly, Markov models can distinguish
between remission and recovery periods by using tempo-
rary states (i.e. 6 more health states). Therefore, a Markov
representation of the problem requires defining at least
72+6 = 78 health states to properly take into considera-
tion primary relevant risk factors (i.e. severity and dura-
tion of the disease).
The efficiency of such a method in more complicated sce-
narios, however, is questionable. For example, what if the
analyst would like to take into consideration an impor-
tant factor of prognosis such as patients' attitude towards
treatment? This would necessitate further splitting each
state in two more states. With every additional factor, the
model becomes increasingly more difficult to handle
properly. Would using a Markovian representation make
it possible to efficiently consider the key factor of suicidal
behaviour? The same reasoning applies: the integration of
all relevant factors into a Markov model may render it too
complex and prone to bias. Markov models have previ-
ously been used to model the cost-effectiveness of relapse
prevention interventions for recurrent depression [18-23].
They have also been used as a tool to portray the epidemi-
ology of depression [24-29]. However, we were unable to
find any Markov model that simultaneously took into
consideration all of the confounding factors just men-
tioned.
These factors are of great interest to researchers and deci-
sion makers alike and, naturally, may merit a more flexi-
ble simulation method. Discrete event simulation models
may be an opportunity to adequately address the limita-
tions of Markov models, and our intention was to assess
the benefits and drawbacks of DES compared with
Markov models.
III.2 Discrete Event Simulation models
Discrete event simulation (DES) is one way of observing
the time- dependent (or dynamic) behaviour of a system
[30-32]. As a cost-effectiveness tool, DES models have
been widely used in various disease areas, including lapar-
oscopic surgery [33], gastric cancer [34], renal diseases
[35], drug abuse [36], HIV transmission [37], early breast
cancer [38,39] and liver transplants [40]. To our knowl-
edge, DES models have not yet been used within the field
of major depression.
Recently, J.J Caro proposed further examination of DES
models as a computational tool for cost-effectiveness
analyses. In doing so he reiterated the key principles of the
method [6]:
 Entities
Entities are the items that evolve through the simulation.
In the clinical simulation of a disease, patients are the
entities. The patient is an explicit element of a discrete
event simulation model. In DES models, patients are
assigned attributes (e.g., age, sex, duration of the disease)
with a specific value (distribution) for each. These values
are defined at the start of the simulation and may be
updated as required: age increases, disease severity levels
rise and fall, the number of depressive events increases,
etc. Other model specifications such as time horizon and
discount rate are encoded in variables. These values may
change during the simulation.
9
Cumulative probability of relapse after remission from  depressive symptoms given the number of prior depression  events (Source: Solomon et al., 2000) Figure 3
Cumulative probability of relapse after remission from 
depressive symptoms given the number of prior depression 
events (Source: Solomon et al., 2000).
Cumulative probability of remission from index episode of  depression (Source: Keller et al., 1998) Figure 4
Cumulative probability of remission from index episode of 
depression (Source: Keller et al., 1998).Cost Effectiveness and Resource Allocation 2006, 4:19 http://www.resource-allocation.com/content/4/1/19
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Markov model synthetic representation Figure 5
Markov model synthetic representation. Cycle length: 1 week. Circles represent health states. Dotted circles represent tem-
porary health states. Arrows represent transition probabilities: 1: Weekly probabilities of remission, according to time spent 
with the illness. 2: Weekly probabilities of relapse according to patient's risk profile.Cost Effectiveness and Resource Allocation 2006, 4:19 http://www.resource-allocation.com/content/4/1/19
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 Events
An event is defined as anything that can happen during
the simulation. This can include occurrence of depressive
symptoms, remission from depressive symptoms, patients
stopping treatment, a suicide attempt, an adverse event,
etc. This concept extends well beyond the transitions in a
Markov model, because the event need not imply a
change in the patient's state. Events can occur sequentially
and/or even simultaneously. They can recur – if this corre-
sponds to clinical reality – and they can change the course
of a given patient's experience by influencing that
patient's attributes and the occurrence of future events.
The rates at which events occur can take on any functional
distribution supported by the data. They can be depend-
ent on any attributes or variables and these functions can
change over time as appropriate.
 Time
The third fundamental component of a DES is time itself.
An explicit simulation clock keeps track of the passage of
time. This makes it possible for the analysts to clearly sig-
nal the start and end of the simulation and to create sec-
ondary clocks that track interim periods such as
depression episode duration or remission periods. By
making time explicit, a DES enables handling time much
more flexibly compared with Markov models because
there is no need to define cycle length.
The model described here belongs to the class of models
that have been described elsewhere as individual sam-
pling models [41,42]. Rather than following an entire
cohort through a model by assigning proportions to dif-
ferent states, discrete event simulation models the path-
way of an individual by sampling probabilities from an a
priori distribution. This results in greater realism in
describing a patient's evolution through the healthcare
system and offers more flexibility in the data requirements
needed to feed the model. DES models provide an alter-
native tool capable of considering multiple risk factors
and non-Markovian structures (i.e. non memory-less sto-
chastic processes). Peter W. Glynn describes a mathemat-
ical formalism for the underlying stochastic process
[43,44], named "Generalized Semi-Markov Process"
(GSMP). A GSMP is an established formalism for mode-
ling continuous-time stochastic discrete event systems.
Throughout the entire simulation, new information
(depending on the triggered events) can be tracked and
stored into a temporary variable, so that future events'
probabilities can be changed to reflect a patient's new clin-
ical and socio-demographic profile. Patients may then
acquire attributes (e.g., a higher risk of relapse) as certain
events occur within the model. The attributes of a particu-
lar patient influence his/her pathway through the simula-
tion, as well as the economic outcomes associated with
the events experienced (e.g., hospitalisation resulting
from a suicide attempt).
Thanks to the strength of the assumptions the technique
offers, and by modelling individual patient pathways,
DES provides a greater degree of flexibility which, when
supplied with adequate data, may allow greater confi-
dence in the results [45].
To examine the properties of DES under practical circum-
stances, we chose to apply them to the dynamics of
depression. The algorithm associated with our problem is
depicted in Figure 6. There are no cycle lengths to declare
and no health states to define. Disease evolution is pic-
tured using events that will trigger a change of health state.
The method chosen to select the next occurring event was
that used by Barton et al. [46], the underlying idea being
"sample times for each possible event and use the mini-
mum" (the rationale being that once the first event has
happened, times to other events may need to be resam-
pled). For each event, therefore, survival distributions
were required assuming that no other event was possible.
A time was sampled for each event and the earliest time
determined which event happened. This is implemented
by considering other events as censored events and the
other times are discarded.
The information required was survival data conditioned
on the number of prior depressive events. The time spent
in the "well" state was obtained by summing the tracked
sampled times leading to relapse. The time spent in the
depressed state was obtained by summing the tracked
sampled times leading to remission. Other tracker varia-
bles make it possible to count the number of relapses or
recurrences occurring during the study period. The patient
started the model with a first depressive event (i.e. no
prior depressive events). The only event that would
remove a patient from the state of depression would be
achieving remission of symptoms. Therefore, a "time to
remission" was sampled based on the patient's history.
The clock advances of the simulated "time to remission"
and a test is performed to check if there is time left to con-
tinue the simulation (according to the fixed time horizon)
or not. Once the patient is symptom-free, he is still subject
to relapse. Therefore, a "time to depression" is sampled
and the clock is advanced to this sampled "time to depres-
sion". If the sampled time was inferior to 24 weeks then
the patient was in "simple remission"(i.e., relapse). If the
sampled time was superior to 24 weeks, then the patient
was in full recovery. Based on these tests, tracker variables
count the number of events that occur, and patient's
attributes are updated accordingly. Figure 6 displays a
graphical representation of the algorithm.
9
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The present DES model reflects a pathway with a very lim-
ited list of possible events: there are no competing events.
This renders the analysis quite simple and as a practical
example makes it possible to visualize the flexibility with
which DES models cope with multiple competing events.
DES models appear to be a powerful means to address
both the problem of a patient's history and the risk for an
illness to persist by using survival distributions condi-
tioned by tracker values. Similarly, remission and recovery
periods can be easily distinguished by tracking the sam-
pled "time to depression" and see if this sampled time (24
weeks, per consensus definitions) is inferior or superior to
a threshold value. If the sampled time to depression was
less than 24 weeks, then the patient could not be in full
recovery and was, therefore, only in a "remission phase".
By implementing various queries, it is possible to define
new trackers that will remember whether the patient was
completely well or not.
DES models are as efficient as Markov models, with per-
haps, slightly more flexibility regarding their implementa-
tion. If the analyst wishes to tackle the problem of
adherence to treatment (a key factor of interest in model-
ling depression), DES models are flexible enough to man-
age this by adding an event to the list of possibilities a
patient is likely to experience (along with its own survival
distribution) and run the model. The sequence of events
experienced by the patient will be randomly generated
according to the event selection method previously out-
lined (i.e. sample "time to events", the first event being
the one selected). This means that key events in depres-
sion such as attempted suicides, adverse events or any
other event for which there is adequate data, can be easily
taken into account.
DES models seem to be a promising simulation tech-
nique, very flexible and easy to follow for any analyst who
may not be familiar either with the key aspects of the dis-
ease or with simulation tools in general. DES models are
able to overcome Markov model limitations particularly
in their ability to take into account multiple events, which
can be crucial when trying to depict disease progression as
close to reality as possible.
IV. Discussion
When modelling the course of disease it is important to
consider as many disease-specific risk factors as possible
in order to provide an informed view of outcomes that
may occur. The word 'may' is important because no model
can predict any outcome with 100% accuracy. Modelling
techniques are evolving in response to criticism aimed at
improving their predictive abilities. Discrete event simula-
tion further contributes to the field. While Markov models
have served – and continue to serve – the scientific and
decision-making communities well, we are of the opinion
that DES also offers additional possibilities for modelling
patients with depression and their progression through
the healthcare system. A frequent criticism of depression
models is that they are often too short and, therefore, una-
ble to accurately reflect the true progression of the disor-
der. In the present case, the DES timeframe was large
enough to capture all events occurring during the disease
span and even beyond (periods of recovery). As such, dis-
tinction between relapses and recurrences (according to
whether the patient is experiencing a new episode of
depression or not) were shown to be important issues to
be taken into consideration in order to more precisely
assess the capacity of a given strategy to delay further risk
of developing depressive symptoms. The number of previ-
ous depressive events, their duration and severity together
with patients' adherence to therapy were also proven to be
key factors that needed be taken into account in the com-
putational framework.
Despite their lack of memory, Markov models managed to
handle the problem of patient history by specifying vari-
ous health states defined according to risk levels (low,
moderate, high risk of relapse). The issue of disease per-
sistence was also addressed, but at the expense of defining
multiple temporary health states. A major drawback, how-
ever, persists in the handling of multiple events. If analysts
truly seek to portray reality as closely as possible, they
should consider scenarios that are more complicated and
that take into account, for example, suicidal behaviour
and patients' attitudes towards treatment. In such situa-
tions they may be more likely to employ more elaborate
modelling methods such as discrete event simulation.
Health service research in general, and economic evalua-
tion in particular, is commonly associated with a lack of
adequate data. In the present case, the intention was to
validate the use of a DES model in a conceptual manner,
i.e. in terms of its computational validity. To numerically
quantify the benefits of DES over Markov models, empir-
ical validation is required. Future research would necessi-
tate comparing simulated results with those obtained
from observational data (i.e. perform an external valida-
tion). Further research should focus on both the internal
and external validity of the conceptual model [47], by col-
lecting adequate data (after systematic review of the liter-
ature), then choosing appropriate statistical distributions
on parameters, and finally by calibrating the model with
reference to results obtained from naturalistic studies.
However, when reliable data is not available, DES may be
a highly suitable information system that could be used to
run a series of different "what if?" scenarios, allowing the
user to understand the interaction of the model parame-
ters, and their effects on the output of interest. For exam-
ple, in the context of exploratory analyses whose purpose
would be to identify preferred health outcomes for inclu-Cost Effectiveness and Resource Allocation 2006, 4:19 http://www.resource-allocation.com/content/4/1/19
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Discrete Event Simulation algorithm Figure 6
Discrete Event Simulation algorithm.Cost Effectiveness and Resource Allocation 2006, 4:19 http://www.resource-allocation.com/content/4/1/19
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sion alongside a clinical trial, DES may help in defining
the requirements of a definitive economic analysis and
determine a data collection strategy.
There are certain limits to DES that deserve to be pointed
out. First, greater flexibility may only be reached at the
expense of supplementary specialist analytic knowledge,
which may reduce the evaluator's direct access to the
model. Also, it may take time to develop, implement and
verify the conceptual model. Moreover, individual-based
models like DES models are highly time-consuming, as
multiple replications are needed to get good estimates of
mean effects. However, variance reduction methods are
available that can reduce the number of replications and
time needed [48]. Finally, DES may induce over-specifica-
tion, whereby possible patient pathways become more
complex than necessary, thus implying an increase in data
requirements.
We deliberately chose here to focus on the methodologi-
cal aspects of the modelling methods, regardless of the
therapeutic strategies and without any costing purpose.
However, costing would be equally feasible in both meth-
ods: DES models would use variables associated to each
event experienced, while Markov models would associate
a monetary value to health states.
In order to provide decision makers with a fully specified
tool aimed at prioritizing actions for relapse prevention in
depression, further work should incorporate, in the form
of a DES model, both clinical and economic data in
accordance with national and international clinical and
pharmacoeconomic guidelines. A practical example of
discrete event simulation model for depression, together
with judicious distribution choice on parameters (among
Weibull, Log-logistic and more generally Gamma distri-
butions) will be the next step of this research, with an aim
towards benchmarking results from a DES model with
those from standard simulation models.
V. Conclusion
When considering the practical examples previously pre-
sented, discrete event simulation appears to be comple-
mentary and appropriate modelling method when
applied to depression. Although discrete event simulation
has a quite long history in industrial operational research
[49-51], it is still not widely used in the assessment of the
value of healthcare interventions. DES could provide a
comprehensive tool to illustrate the course of depression,
thus allowing greater flexibility in depicting the cost-effec-
tiveness of prevention interventions for recurrent depres-
sion. In general, the greatest advantages DES has to offer
are that it allows the analyst to model more complex and
dynamic systems compared with other types of modelling
and that it permits experiments that might not otherwise
be feasible ("what if?" scenarios) and may provide addi-
tional support for expected value of information (EVPI)
analyses. The greater flexibility of DES also enables the
model to capture more details about the uncertainty in the
system being modelled.
Conflicts of interest
This manuscript is part of the doctoral thesis requirements
of Agathe Le Lay, H. Lundbeck A/S provided a grant for
this study. Clement Francois and Nicolas Despiegel are
employees of H. Lundbeck A/S. Gerard Duru declares no
conflict of interest.
Acknowledgements
The authors gratefully acknowledge John Cochran for his editorial assist-
ance.
References
1. Paykel ES, Brugha T, Fryers T: Size and burden of depressive dis-
orders in Europe.  Eur Neuropsychopharmacol 2005, 15(4):411-423.
2. Murray CJ, Lopez AD: Alternative projections of mortality and
disability by cause 1990–2020: Global Burden of Disease
Study.  Lancet 1997, 349(9064):1498-1504.
3. Segal ZV, Pearson JL, Thase ME: Challenges in preventing relapse
in major depression. Report of a National Institute of Mental
Health Workshop on state of the science of relapse preven-
tion in major depression.  J Affect Disord 2003, 77(2):97-108.
4. Drummond M, Jonsson B, Rutten F: The role of economic evalu-
ation in the pricing and reimbursement of medicines.  Health
Policy 1997, 40(3):199-215.
5. Sonnenberg FA, Beck JR: Markov models in medical decision
making: a practical guide.  Med Decis Making 1993,
13(4):322-338.
6. Caro JJ: Pharmacoeconomic analyses using discrete event
simulation.  Pharmacoeconomics 2005, 23(4):323-332.
7. Keller MB, Boland RJ: Implications of failing to achieve success-
ful long-term maintenance treatment of recurrent unipolar
major depression.  Biol Psychiatry 1998, 44(5):348-360.
8. Akerblad AC, Bengtsson F, von Knorring L, Ekselius L: Response,
remission and relapse in relation to adherence in primary
care treatment of depression: a 2-year outcome study.  Int
Clin Psychopharmacol 2006, 21(2):117-124.
9. Keller MB: The long-term treatment of depression.  J Clin Psy-
chiatry 1999, 60(Suppl 17):41-45.
10. Solomon DA, Keller MB, Leon AC, Mueller TI, Lavori PW, Shea MT,
et al.: Multiple recurrences of major depressive disorder.  Am
J Psychiatry 2000, 157(2):229-233.
11. Keller MB, Lavori PW, Rice J, Coryell W, Hirschfeld RM: The per-
sistent risk of chronicity in recurrent episodes of nonbipolar
major depressive disorder: a prospective follow-up.  Am J Psy-
chiatry 1986, 143(1):24-28.
12. Olfson M, Marcus SC, Tedeschi M, Wan GJ: Continuity of antide-
pressant treatment for adults with depression in the United
States.  Am J Psychiatry 2006, 163(1):101-108.
13. Melfi CA, Chawla AJ, Croghan TW, Hanna MP, Kennedy S, Sredl K:
The effects of adherence to antidepressant treatment guide-
lines on relapse and recurrence of depression.  Arch Gen Psychi-
atry 1998, 55(12):1128-1132.
14. Marcus SM, Young EA, Kerber KB, Kornstein S, Farabaugh AH, Mitch-
ell J, et al.: Gender differences in depression: findings from the
STAR*D study.  J Affect Disord 2005, 87(2–3):141-150.
15. Beck JR, Pauker SG: The Markov process in medical prognosis.
Med Decis Making 1983, 3(4):419-458.
16. NICE guidance on Depression: management of depression in
primary and secondary care.  2004.
17. Kennedy SH, Lam RW, Cohen NL, Ravindran AV: Clinical guide-
lines for the treatment of depressive disorders. IV. Medica-
tions and other biological treatments.  Can J Psychiatry 2001,
46(Suppl 1):38S-58S.Cost Effectiveness and Resource Allocation 2006, 4:19 http://www.resource-allocation.com/content/4/1/19
Page 11 of 11
(page number not for citation purposes)
18. Dardennes R, Lafuma A, Fagnani F, Pribil C, Bisserbe JC, Berdeaux G:
Economic Assessment of a Maintenance Treatment Strat-
egy in Prevention of Recurrent Depressive Disorder.  Value in
Health 2000, 3(1):40-47.
19. Hatziandreu EJ, Brown RE, Revicki DA, Turner R, Martindale J, Levine
S, et al.: Cost-Utility of Maintenance Treatment of Recurrent
Depression with Sertraline Versus Episodic Treatment with
Dothiepin.  Pharmacoeconomics 1994, 5(3):249-264.
20. Kamlet MS, Paul N, Greenhouse J, Kupfer D, Frank E, Wade M: Cost-
Utility Analysis of Maintenance Treatment for Recurrent
Depression.  Controlled Clinical Trials 1995, 16(1):17-40.
21. Lafuma A, Dardennes R, Fagnani F, Pribil C, Bisserbe JC, Berdeaux G:
Economic assessment of maintenance treatment of recur-
rent depressive disorder with milnacipran versus episode
treatment.  Encephale-Revue de Psychiatrie Clinique Biologique et Ther-
apeutique 1999, 25(5):401-407.
22. Nuijten M, Hardens M, Souetre E: A Markov Process Analysis
Comparing the Cost-Effectiveness of Maintenance Therapy
with Citalopram Versus Standard Therapy in Major Depres-
sion.  Pharmacoeconomics 1995, 8(2):159-168.
23. Nuijten M, Hadjadjeba L, Evans C, van den Berg J: Cost effective-
ness of fluvoxamine in the treatment of recurrent depres-
sion in France.  Pharmacoeconomics 1998, 14(4):433-445.
24. Patten SB, Lee RC: Epidemiological theory, decision theory and
mental health services research.  Soc Psychiatry Psychiatr Epidemiol
2004, 39(11):893-898.
25. Patten SB, Lee RC: Towards a dynamic description of major
depression epidemiology.  Epidemiol Psichiatr Soc 2004,
13(1):21-28.
26. Patten SB, Lee RC: Refining estimates of major depression inci-
dence and episode duration in Canada using a Monte Carlo
Markov model.  Med Decis Making 2004, 24(4):351-358.
27. Patten SB: Modelling major depression epidemiology and
assessing the impact of antidepressants on population
health.  Int Rev Psychiatry 2005, 17(3):205-211.
28. Patten SB: Markov models of major depression for linking psy-
chiatric epidemiology to clinical practice.  Clin Pract Epidemol
Ment Health 2005, 1(1):2.
29. Patten SB, Lee RC: Describing the longitudinal course of major
depression using Markov models: data integration across
three national surveys.  Popul Health Metr 2005, 3:11.
30. Davies R: An assessment of models of a health system.  J Oper
Res Soc 1985, 36(8):679-687.
31. Jacobson S, Hall S, Swisher J: Discrete Event Simulation of
Health Care Systems.  In Delay Management in Healthcare Systems
Edited by: Hall R. Springer in Health Care Management; 2006. 
32. Law A, Kelton W: Simulation Modeling and Analysis 3rd edition. Mc
Graw Hill; 2000. 
33. Stahl JE, Rattner D, Wiklund R, Lester J, Beinfeld M, Gazelle GS:
Reorganizing the system of care surrounding laparoscopic
surgery: a cost-effectiveness analysis using discrete-event
simulation.  Med Decis Making 2004, 24(5):461-471.
34. Roderick P, Davies R, Raftery J, Crabbe D, Pearce R, Patel P, et al.:
Cost-effectiveness of population screening for Helicobacter
pylori in preventing gastric cancer and peptic ulcer disease,
using simulation.  J Med Screen 2003, 10(3):148-156.
35. Huybrechts KF, Caro JJ, Wilson DA, O'Brien JA: Health and eco-
nomic consequences of sevelamer use for hyperphos-
phatemia in patients on hemodialysis.  Value Health 2005,
8(5):549-561.
36. Zarkin GA, Dunlap LJ, Hicks KA, Mamo D: Benefits and costs of
methadone treatment: results from a lifetime simulation
model.  Health Econ 2005, 14(11):1133-1150.
37. Rauner M, Brailsford S, Flessa S: Use of discrete-event simulation
to evaluate strategies for the prevention of mother-to-child
transmission of HIV in developing countries.  Journal of the
Operational Research Society 2005, 56:222-233.
38. Brown J, Karnon J, Eldabi T, Paul RJ: Using modelling in a phased
approach to the economic evaluation of adjuvant therapy for
early breast cancer. ABC Trial Steering Committee.  Crit Rev
Oncol Hematol 1999, 32(2):95-103.
39. Karnon J, Brown J: Selecting a decision model for economic
evaluation: a case study and review.  Health Care Manag Sci 1998,
1(2):133-140.
40. Ratcliffe J, Young T, Buxton M, Eldabi T, Paul R, Burroughs A, et al.: A
simulation modelling approach to evaluating alternative pol-
icies for the management of the waiting list for liver trans-
plantation.  Health Care Manag Sci 2001, 4(2):117-124.
41. Barton P, Bryan S, Robinson S: Modelling in the economic evalu-
ation of health care: selecting the appropriate approach.  J
Health Serv Res Policy 2004, 9(2):110-118.
42. Brennan A, Chick SE, Davies R: A taxonomy of model structures
for economic evaluation of health technologies.  Health Econ
2006, 15:1295-1310.
43. Glynn P: On the role of generalized semi-Markov processes in
simulation output analysis.  Winter Simulation Conference – Pro-
ceedings of the 15th conference on Winter simulation 1983, 1:39-44.
44. Glynn P: A GSMP formalism for discrete event systems.  Pro-
ceedings of the IEEE 1989, 77(1):14-23.
45. Eddy DM: Accuracy versus transparency in pharmacoeco-
nomic modelling: finding the right balance.  Pharmacoeconomics
2006, 24(9):837-844.
46. Barton P, Jobanputra P, Wilson J, Bryan S, Burls A: The use of mod-
elling to evaluate new drugs for patients with a chronic con-
dition: the case of antibodies against tumour necrosis factor
in rheumatoid arthritis.  Health Technol Assess 2004, 8(11):1-104.
47. Sargent R: Validation and verification of simulation models.
Proceedings of the 2004 Winter Simulation Conference 2004.
48. Shechter S, Schaefer A, Braithwaite R, Roberts M: Increasing the
Efficiency of Monte Carlo Cohort Simulationswith Variance
Reduction Techniques. Technical note.  Medical Decision Making
2006.
49. Christodoulou K, Vlahos K: Variable structure modelling of
dynamic industry systems.  Journal of the Operational Research Soci-
ety 2000, 51:1029-1040.
50. Roy R, Arunachalam R: Parallel discrete event simulation algo-
rithm for manufacturing supply chains.  Journal of the Operational
Research Society 2004, 55:622-629.
51. Davis RM: An interactive simulation in the Health Service.
Journal of the Operational Research Society 1985, 36(7):597-606.